Ascletis Pharma Inc.

Investors

Voluntary Announcement - Ascletis Announces Initiation of Phase I Study in U.S. for Oral Amylin Receptor Peptide Agonist ASC36 for the Treatment of Obesity
2026-09-08
Voluntary Announcement - Inclusion in the Hong Kong Stock Connect List under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect Programs
2026-09-07
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2026
2026-09-03
2026 Interim Results
2026-08-31
Voluntary Announcement - Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management
2026-08-30
Profit Warning
2026-08-21
Voluntary Announcement - Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation of ASC36 and GLP-1R/GIPR Peptide Agonist ASC35
2026-08-10
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2026
2026-08-04
Voluntary Announcement - Ascletis Announces Initiation of Global Phase III for Oral Small Molecule GLP-1, ASC30 and Positive Preclinical Data for Its First-in-Class Oral Small Molecule GLP-1/GIP/Amylin Fixed-Dose Combination
2026-08-03
Notice of Board Meeting
2026-08-03

1

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备11050387号-1 Cookie Settings